Insulin is among the highest-alert medications in any hospital formulary. It requires patient-specific management across every unit, every shift, and every care setting. Yet for most health systems, glycemic care remains fragmented manual calculations at the bedside, inconsistent protocols from one unit to the next, and quality data that arrives weeks after preventable events have already occurred.
GlytecOne is designed to address this challenge. Glytec’s unified Intelligent Glycemic Management platform connects four capabilities, Care Enablement, Decision Support, Performance Insights, and Population Health, all in one integrated ecosystem. For clinical leaders, that means consistent, FDA-cleared dosing guidance at the point of care via Glucommander. For operations and quality leaders, it means current visibility into glycemic performance across the enterprise.
This post examines what each of the four capabilities delivers, who it serves, and how they work together to move health systems from reactive, manual glycemic workflows toward a safety-first, unified model. For additional resources and case studies, visit glytec.com/information-hub.
Inpatient glycemic care in most health systems remains fragmented — unit-by-unit variation, manual calculations at the bedside, and quality data that surfaces problems retrospectively rather than in time to prevent them.
GlytecOne, Glytec’s unified Intelligent Glycemic Management platform, connects four capabilities — Care Enablement, Decision Support, Performance Insights, and Population Health — to help health systems manage glycemic care consistently from bedside to enterprise.
The platform’s clinical foundation is Glucommander, FDA-cleared as a Class II Software as a Medical Device since 2006 for IV use and 2010 for subcutaneous use, which provides insulin dosing recommendations for clinician review and confirmation.
GlytecOne integrates directly with Epic, Oracle Health, and MEDITECH — no additional charting steps required — allowing bedside data to flow to executive performance dashboards without clinical workflow disruption.
Across more than 400 hospitals, Glucommander has supported insulin dosing management for more than 867,000 patients, with documented reductions in severe hypoglycemia, nursing workflow burden, and costs at named reference institutions. Individual results may vary.
The Problem with Fragmented Glycemic Care
Glycemic care touches a significant portion of any inpatient population. Clinical data indicates that up to one in three hospitalized patients has diabetes, and approximately 40 percent of hospitalized patients may meet the clinical indications for insulin therapy. Despite this scope, glycemic management in most health systems still relies on manual calculations, static paper protocols, and unit-specific workflows that produce wide variation in care.
The consequences extend in two directions. At the bedside, manual insulin management creates cognitive burden for clinical teams and increases the risk of preventable adverse drug events. At the leadership level, quality data typically surfaces through retrospective reports — identifying problems after harm has already occurred rather than in time to prevent it.
GlytecOne is designed to help address this fragmentation by connecting bedside dosing, clinical visibility, performance analytics, and population-level oversight into a single platform.
Care Enablement — FDA-Cleared Dosing at the Point of Care
The clinical foundation of GlytecOne is Care Enablement, powered by Glucommander — FDA-cleared as a Class II Software as a Medical Device (SaMD) since 2006 for IV insulin use and 2010 for subcutaneous use.
Glucommander provides insulin dosing recommendations for clinician review and confirmation. It supports standardized, evidence-based dosing at the point of care while keeping the clinician in control at every step. Every recommendation requires clinical review and confirmation before it is acted upon.
The clinical case is straightforward. A nurse managing multiple critical patients — often at the end of a 12-hour shift — is being asked to perform complex calculations for patients whose metabolic status is changing in real time. A patient admitted for pneumonia and placed on steroids will experience glycemic shifts that a static paper protocol cannot safely accommodate. Care Enablement provides dosing guidance that reflects current patient response without adding to the clinical team’s cognitive burden.
Glucommander is a prescription-only, FDA-cleared Class II SaMD. Individual results may vary.
Decision Support — Current Visibility Across the Patient Panel
Consistent bedside dosing addresses individual patient risk. Clinical teams also need current visibility across their entire patient panel — to identify which patients are trending outside target glycemic range and to organize their priorities without additional chart navigation.
The Decision Support capability, delivered through Command Center, organizes current and historical glucose data across patient panels into structured displays layered directly into existing EHR workflows. Clinicians do not navigate to a separate system. Command Center presents patient information and trends to support awareness and prioritization, helping teams identify patients whose data patterns may warrant structured review.
Alert fatigue is a real operational risk. When clinical teams are overwhelmed with notifications, the value of each alert erodes. Command Center is designed to surface relevant clinical information without adding to an already crowded workday — structured to reduce noise, not increase it.
Command Center presents trends and information for clinician awareness. It does not generate real-time intervention alerts, determine clinical urgency, or recommend specific treatment actions for individual patients.
Performance Insights — From Bedside Events to Enterprise Accountability
The third capability translates bedside and unit-level data into enterprise-level performance analytics. Performance Insights aggregates glycemic outcomes across the health system, giving clinical and operational leadership current, measurable visibility into how the program is performing.
For CMOs and CQOs, this means moving away from retrospective harm reports as the primary quality tool. Performance Insights delivers benchmarks aligned to CMS glycemic quality measures, including the severe hypoglycemia and hyperglycemia eCQMs now mandatory under the 2026 CMS IPPS final rule. Performance data is current, auditable, and reportable — designed for the accountability standards CMS now requires.
For CFOs, the data connection is direct. Severe glycemic events extend length of stay, increase readmission risk, and generate costs that compound across a patient population. Performance Insights provides visibility into where clinical gaps exist and where their financial impact surfaces — giving leadership the evidence to make defensible, board-level decisions.
No Double Charting — EHR Integration Across Epic, Oracle Health, and MEDITECH
A persistent concern with enterprise clinical platforms is the documentation burden placed on clinical staff. If nursing teams must log into a separate system or record data twice to fuel leadership dashboards, adoption fails — and the clinical benefit the platform is designed to deliver fails with it.
GlytecOne integrates directly with Epic, Oracle Health, and MEDITECH. Clinical teams work within the tools they already use. Bedside data flows through the platform to unit-level visibility and executive dashboards without requiring additional documentation steps.
This design reflects a foundational operational principle: if the safe workflow is not also the efficient workflow, clinical teams do not have the bandwidth to sustain it consistently. GlytecOne is built so that evidence-based glycemic care and clinical efficiency are the same path.
Population Health — Enterprise Governance Across Facilities and Care Settings
The fourth capability extends GlytecOne’s reach beyond a single facility. The Population Health pillar supports health systems in managing glycemic outcomes across multiple facilities and care settings, including transitions between inpatient and post-acute environments.
This matters as health systems expand their operational footprint and take on value-based care arrangements. Inpatient glycemic performance connects directly to quality reporting requirements, health plan partnerships, and total cost-of-care goals — and the risk of care inconsistency grows at every transition point.
Sentara Healthcare documented a 57 percent reduction in hypoglycemia across 12 hospitals using GlytecOne, demonstrating that the platform’s clinical and operational outcomes hold at enterprise scale, not just in single-facility deployments. Individual results may vary.
GlytecOne as a Unified System, Not Four Separate Tools
The four capabilities are not independent tools assembled for a product catalog. They share a single data architecture: dosing data from Care Enablement flows through Decision Support’s patient-panel visibility into Performance Insights’ enterprise analytics and Population Health’s multi-facility governance.
The practical implication for health system leaders is important. Enterprise-level glycemic performance — including CMS eCQM readiness and the financial outcomes it enables — is downstream of bedside reality. It depends on the consistency of the dosing, the quality of the clinical decision support, and the reliability of the workflow at the unit level.
Addressing the boardroom metrics starts with addressing the manual workflows at the nursing station.
For citations and details, see the Glytec Resources Page.
See where manual glycemic workflows may be creating avoidable risk in your organization.
For additional resources, visit glytec.com/information-hub or explore The Drip podcast at glytec.com/the-drip for the full source discussion.
What is GlytecOne?
GlytecOne is Glytec’s unified Intelligent Glycemic Management platform. It connects four capabilities — Care Enablement, Decision Support, Performance Insights, and Population Health — to help health systems manage inpatient glycemic care consistently from the bedside to enterprise-level analytics and population health oversight.
What is Glucommander and how does it support bedside insulin dosing?
Glucommander is an FDA-cleared Class II Software as a Medical Device (SaMD) that provides insulin dosing recommendations for clinician review and confirmation. It has held continuous FDA clearance since 2006 for IV use and 2010 for subcutaneous use, with zero FDA recalls in 20 years. Every recommendation requires clinician review before action.
Does GlytecOne or Glucommander replace clinical judgment?
No. GlytecOne supports clinical judgment — it does not replace it. Glucommander provides dosing recommendations that clinicians must review and confirm at every step. The platform is designed to reduce cognitive burden and support evidence-based decision-making while the clinician retains full control of every patient care decision.
What EHR systems does GlytecOne integrate with?
GlytecOne integrates directly with Epic, Oracle Health, and MEDITECH. Clinical teams continue working within their existing EHR workflows without additional documentation steps. Bedside data flows through the platform to unit-level and enterprise-level performance dashboards without requiring double charting from nursing or clinical staff.
What is Command Center in the GlytecOne platform?
Command Center is the Decision Support component of GlytecOne. It organizes current and historical glucose data across patient panels into structured displays within existing EHR workflows to support clinician awareness and prioritization. Command Center presents trends for clinician review — it does not generate real-time intervention alerts or determine clinical urgency.
How does GlytecOne support CMS glycemic eCQM readiness?
GlytecOne’s Performance Insights capability delivers benchmarks aligned to CMS glycemic quality measures, including the severe hypoglycemia and hyperglycemia eCQMs mandatory under the 2026 CMS IPPS final rule. This shifts quality oversight from retrospective harm reports to current, auditable performance data that is reportable and defensible at the board level.
How many patients have been managed using Glucommander?
Glucommander has supported insulin dosing management for more than 867,000 patients across 400+ hospitals nationwide. This deployment scale supports an extensive published clinical evidence base that informs both the algorithm and the implementation expertise Glytec provides with every deployment. Individual results may vary.
What is the Population Health pillar of GlytecOne?
The Population Health pillar supports health systems in managing glycemic outcomes across multiple facilities and care settings, including transitions between inpatient and post-acute environments. It connects inpatient glycemic performance to value-based care goals, health plan partnerships, and quality reporting requirements, providing governance at enterprise scale.
- GlytecOne is a unified Intelligent Glycemic Management platform connecting four capabilities — Care Enablement, Decision Support, Performance Insights, and Population Health — designed to move health systems from fragmented, manual glycemic workflows toward consistent, safety-first clinical and operational performance.
- Glucommander, the FDA-cleared clinical foundation of GlytecOne, is a Class II Software as a Medical Device that provides insulin dosing recommendations for clinician review and confirmation, with continuous FDA clearance since 2006 for IV use and 2010 for subcutaneous use, and zero FDA recalls in 20 years.
- Command Center, GlytecOne’s Decision Support component, organizes current and historical glucose data across patient panels within existing EHR workflows — presenting trends and information for clinician awareness and prioritization without adding to alert burden or requiring separate chart navigation.
- GlytecOne integrates directly with Epic, Oracle Health, and MEDITECH — no double charting required — allowing bedside data to flow to enterprise performance dashboards within the workflows clinical teams already use.
- Performance Insights delivers benchmarks aligned to CMS glycemic quality measures, including the severe hypoglycemia and hyperglycemia eCQMs mandatory under the 2026 IPPS rule, shifting quality oversight from retrospective harm reports to current, auditable performance data.
- Glucommander has supported insulin dosing management for more than 867,000 patients across 400+ hospitals nationwide; Sentara Healthcare documented a 57 percent reduction in hypoglycemia across 12 hospitals using GlytecOne. Individual results may vary.
